Folkert W. Asselbergs
Folkert W. Asselbergs is professor of precision medicine in cardiovascular disease at Institute of Cardiovascular Science, UCL, Director NIHR BRC Clinical Research Informatics Unit at UCLH, professor of cardiovascular genetics and consultant cardiologist at the department of Cardiology, University Medical Center Utrecht, and chief scientific officer of the Durrer Center for Cardiovascular Research, Netherlands Heart Institute. Prof Asselbergs published more than 275 scientific papers and obtained funding from leDucq foundation, British and Dutch Heart Foundation, EU (FP7, ERA-CVD, IMI, BBMRI), and RO1 National Institutes of Health.
Prof Asselbergs research program focuses on precision medicine in predominantly hospital patients using EHR data and -omics. He is scientific coordinator of IMI BigData-at-Heart (www.bigdata-heart.eu) program that aims to deliver clinically relevant disease phenotypes and outcomes, scalable insights from real-world evidence and insights driving drug development and personalised medicine through advanced big-data analytics. He is member of a large number of consortia and (co-) founded several consortia of which igenetrain (www.igenetrain.org), and genius-chd (www.genius-chd.org) are the most prominent and recent ones.
Prof Asselberg is a member of the Covid-19 Open AI Consortium (COAI), an initiative of the Franco-American company Owkin, to bring breakthrough medical discoveries and actionable findings to the fight against the Covid-19 pandemic. COAI aims to increase collaborative research, to accelerate clinical development of effective treatments for Covid-19, and to share all of its findings with the global medical and scientific community. COAI will unite collaborators: academic institutions, researchers, data scientists and industrial partners, to fight the Covid-19 pandemic.
Prof Asselbergs research program focuses on precision medicine in predominantly hospital patients using EHR data and -omics. He is scientific coordinator of IMI BigData-at-Heart (www.bigdata-heart.eu) program that aims to deliver clinically relevant disease phenotypes and outcomes, scalable insights from real-world evidence and insights driving drug development and personalised medicine through advanced big-data analytics. He is member of a large number of consortia and (co-) founded several consortia of which igenetrain (www.igenetrain.org), and genius-chd (www.genius-chd.org) are the most prominent and recent ones.
Prof Asselberg is a member of the Covid-19 Open AI Consortium (COAI), an initiative of the Franco-American company Owkin, to bring breakthrough medical discoveries and actionable findings to the fight against the Covid-19 pandemic. COAI aims to increase collaborative research, to accelerate clinical development of effective treatments for Covid-19, and to share all of its findings with the global medical and scientific community. COAI will unite collaborators: academic institutions, researchers, data scientists and industrial partners, to fight the Covid-19 pandemic.